Open Calls

Ebola, Big Data, Childhood Cancers and Medicines Safety Feature in New IMI Call

Innovative Medicines InitiativeThe Innovative Medicines Initiative (IMI) has launched two Calls for proposals that will advance medicines development in critical areas such as Ebola, childhood cancers, neurological disorders, and eye disease. The Calls will also add to IMI's growing programme on Big Data for Better Outcomes.

Ebola - The recent Ebola outbreak in western Africa infected over 28 000 people and killed over 11 000, starkly highlighting the urgent need for new vaccines, treatments and diagnostic tests for this devastating disease. IMI and others responded to this emergency by rapidly launching Ebola research programmes. However, further efforts are needed to ensure the world is equipped to stop future outbreaks in their tracks. With this in mind, IMI is launching a €70 million open Call for proposals that invites consortia to submit proposals covering diverse aspects of Ebola research, including the development of vaccines, diagnostic tests, and treatments. The resulting projects should be able to capture emerging scientific advances and turn them into healthcare interventions that will increase our readiness to react to future outbreaks of Ebola or related diseases.

In parallel, IMI is launching a standard Call for proposals with seven topics, including two on big data.

Big data for better outcomes - In addition to a topic to coordinate and support the entire big data programme, the Call includes a topic that aims to improve clinical outcomes for people with heart disease through better access to, and use of data.

Childhood cancers - Today, 20% of childhood cancers remain incurable and survivors of childhood cancers often experience long-term side effects. This topic will deliver a platform of research tools to facilitate the identification of potential drugs for childhood cancers.

Alzheimer's and Parkinson's diseases - The focus of this topic is on how protein tangles, which are hallmarks of both diseases, spread throughout the brain. The project results will therefore increase our chance of identifying new targets for drugs.

Chronic pain - Neuropathic pain affects 6-8% of the population and is extremely hard to treat. This topic focuses on improving our understanding of the underlying causes of neuropathic pain, something that will aid in the development of new treatments.

Eye diseases - There are currently no effective treatments for dry age-related macular degeneration (AMD), and it is one of the leading causes of blindness worldwide. This topic aims to develop new and better measures of patients' disease status that could be used when testing new drugs in clinical trials.

Medicines safety - This topic aims to advance the use of imaging in assessments of medicines safety. Among other things, this would improve medicines safety, add to our understanding of why medicines sometimes cause toxicity, and reduce the use of animals in research.

Pierre Meulien, IMI Executive Director commented: "These Calls for proposals demonstrate the added value of IMI. Excellent science exists in all of these research areas, but only by bringing together experts from industry, academia, small biotechs, patient groups, and others can we hope to translate world-class science into improved health for patients."

The Ebola Call (IMI 2 - Call 8) has a total budget of €70 million from IMI that will be available from the first cut-off date of the two year open application period. The other Call (IMI 2 - Call 7) has a budget from IMI of €46.8 million; this will go to eligible universities, small companies, and patient organisations, etc. This will be matched by €46.8 million from the EFPIA companies in the projects; these companies do not receive any money from IMI but contribute largely 'in kind', e.g. by donating their researchers' time, or access to equipment and resources.

IMI 2 - Call 7
Topics on safety, Alzheimer's/Parkinson's diseases, pain, eye diseases, childhood cancers, big data
Deadline for submitting proposals: 17 March 2016
Call documents and details of how to apply: http://www.imi.europa.eu/content/stage-1-18

IMI 2 - Call 8
Ebola and related diseases This Call for proposals will remain open for two years with the following cut-off dates for the submission of proposals: 16 March 2016, 15 September 2016, 16 March 2017, 14 September 2017, 15 March 2018.
Call documents and details of how to apply: http://www.imi.europa.eu/content/imi-2-call-8

About the Innovative Medicines Initiative
The Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. It does this by facilitating collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators.

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). Through the IMI 2 programme, IMI has a budget of €3.3 billion for the period 2014-2024. Half of this comes from the EU's research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects 'in kind', for example by donating their researchers' time or providing access to research facilities or resources.

Most Popular Now

Smartphone Apps not so Smart at Hel…

You might not want to depend on your smartphone app alone to help you avoid or achieve pregnancy, say the authors of a new study. A review of nearly 100 fertility awarene...

Read more

Philips and Spanish Hospital Campus…

Royal Philips (NYSE: PHG, AEX: PHIA) has announced the successful start of a long-term strategic partnership with Servicio Andaluz de Salud (Andalusian Health Service, Sp...

Read more

Artificial Intelligence may Aid in …

Machine learning is a type of artificial intelligence that allows computer programs to learn when exposed to new data without being programmed. Now, researchers in The Ne...

Read more

Your Wearable Devices Reveal Your P…

Wearable devices can give away your passwords, according to new research. In the paper "Friend or Foe?: Your Wearable Devices Reveal Your Personal PIN" scientists from Bi...

Read more

Electronic Tablets Speed Stroke Car…

A clinical trial testing mobile videoconferencing as a means for physicians to diagnose stroke patients while they're being transported to the hospital has found that a t...

Read more

'Big Data' Study Discovers Earliest…

Scientists at the Montreal Neurological Institute and Hospital have used a powerful tool to better understand the progression of late-onset Alzheimer's disease (LOAD), id...

Read more

Welch Allyn and Patientrack Collabo…

A national focus on reducing avoidable patient harm in NHS hospitals is to benefit from a new collaboration between two vital signs monitoring and technology specialists...

Read more

Can a Computer Game Train Your Brai…

That's the question Drexel University researchers hope to answer with one of two new studies launching this month. They have developed a computer game and smartphone app ...

Read more

Study on the Impact of Marketing th…

The European Online Games, Social Media and Mobile Application sector has grown substantially in recent years and children are exposed to increasingly sophisticated marke...

Read more

Philips Teams Up with Visiopharm to…

Royal Philips (NYSE: PHG, AEX: PHIA) has signed a licensing agreement with Visiopharm to offer their breast cancer panel software algorithms [1] with Philips IntelliSite ...

Read more

Tackling Youth Obesity by Playing G…

Imagine a companion who is able to constantly motivate you, actively encourages you and changes your bad habits into healthy ones. A companion who is always present and w...

Read more

A 'Big Data' Approach to Developing…

Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study publi...

Read more

Digest Newsletter

Subscribe to our weekly Newsletter and stay updated on the latest eHealth News. Subscribe now, it's free!
© eHealthNews.eu 2006 - 2016